6th AnnualInvitation Only
CLL-Lymphoma
USFocus Meeting 2027
Two days, 48 people, one room.
May 7 to 8, 2027
San Diego, CA
Dates
May 7-8, 2027
Two-day program
Venue
San Diego, CA
Hotel TBC
Audience
48 by invitation
24 KOLs & 24 fellows
Format
8 sessions · 24 talks
Expert talks + moderated panels
A Curated Room: The People Shaping Practice
This 6th annual, invitation-only meeting convenes a deliberately small faculty: 24 leading CLL and lymphoma KOLs alongside 24 hand-selected fellows and junior faculty, the clinicians defining today’s standards and the ones who will define the next decade’s, in one room for two days.
The science tracks where treatment is moving: bispecific antibodies in earlier-line combinations, ctDNA and MRD as treatment-decision tools, degraders and next-generation BTK and BCL2 targeting, and molecular classification driving frontline selection. Every session pairs expert talks with a moderated panel, sustained, close-quarters engagement rather than a lecture hall.
Bispecific AntibodiesctDNA & MRDBTK, BCL2 & DegradersMolecular ClassificationRisk-Adapted FrontlineCLL · DLBCL · MCL · Indolent Lymphoma
Meeting Co-Chairs
Christopher Flowers
MD Anderson Cancer Center, Houston, TX
Susan O’Brien
UCI Health, Orange, CA
Faculty Drawn From
MD Anderson · Memorial Sloan Kettering · Stanford · City of Hope · NYU Langone and other leading US cancer centers
48
Invited attendees only, sustained access, not a crowd
1:1
KOLs to rising faculty, a hand-picked balance in every session
14
Established US Focus Meetings behind it, a proven platform, not a one-off
CLL-Lymphoma US Focus Meeting 2027
Faculty
Listed alphabetically by surname
Ash Alizadeh
Stanford University, Stanford, CA
Elizabeth Budde
City of Hope, Duarte, CA
Carla Casulo
Wilmot Cancer Institute, Rochester, NY
Dai Chihara
MD Anderson Cancer Center, Houston, TX
Catherine Diefenbach
NYU Langone Health, New York, NY
Christopher Flowers
MD Anderson Cancer Center, Houston, TX
Michael Green
MD Anderson Cancer Center, Houston, TX
Anita Kumar
Memorial Sloan Kettering, New York, NY
Loretta Nastoupil
Southwest Oncology, CommonSpirit Mercy, Durango, CO
Susan O’Brien
UCI Health, Orange, CA
Mark Roschewski
Memorial Sloan Kettering, New York, NY
David Scott
BC Cancer, Vancouver, BC
Sonali Smith
University of Chicago, Chicago, IL
Jason Westin
MD Anderson Cancer Center, Houston, TX
Dana-Farber Cancer Institute, Boston, MA
NYU Langone Health, New York, NY
Cedars-Sinai, Los Angeles, CA
UCLA, Los Angeles, CA
Mount Sinai Medical Center, Miami Beach, FL
Dana-Farber Cancer Institute, Boston, MA
UC Irvine, Orange, CA
MD Anderson Cancer Center, Houston, TX
MD Anderson Cancer Center, Houston, TX
Massachusetts General Hospital, Boston, MA
Two Days, Eight Sessions
Agenda
15 min
5 min
30 min
20 min
65 min
Day One · Friday, May 7, 2027
Ohio State University, Columbus, OH
Agenda & Faculty to be Announced
ModeratorTBC
Endometrial Molecular Classification
Casey CosgroveOhio State University, Columbus, OH
Multiplex Biomarker Workflow for Ovarian Cancer
Barrett LawsonMD Anderson Cancer Center, Houston, TX
HRD/BRCA Testing: Assays, Spatial Heterogeneity & Front-Line PARPi Access (± RNA/fusions)
Dana ChaseUCLA David Geffen School of Medicine, Los Angeles, CA
Young Investigator Case Presentation
TBD
Panel Discussion
ModeratorTBC
Adjuvant Therapy for dMMR (NRG-GY020 Readout)
Floor BackesOhio State University, Columbus, OH
Chemo/ICI in Advanced Recurrent Disease + Mechanisms of Resistance
Ramez EskanderUC San Diego, La Jolla, CA
ICI Instead of Chemo in dMMR
Brian SlomovitzMount Sinai Medical Center, Miami Beach, FL
Young Investigator Case Presentation
TBD
Panel Discussion
ModeratorTBC
Adjuvant Therapy for pMMR by Molecular Subgroup (RAINBO, PORTEC-4)
Brad CorrUniversity of Colorado Anschutz, Aurora, CO
Non-dMMR Advanced Recurrent 1L & Optimal Maintenance
Kathleen MooreFred & Pamela Buffett Cancer Center, Omaha, NE
2L+ Endometrial Cancer ADCs & Small Molecules
Bhavana PothuriNYU Langone Health, New York, NY
Young Investigator Case Presentation
TBD
Panel Discussion
ModeratorTBC
What ADCs Are: Beyond Target, Payload & Linker
Paolo TarantinoDana-Farber Cancer Institute, Boston, MA
Toxicities & Need for MDT: ILD, OM, Ocular
BJ RimelCedars-Sinai, Los Angeles, CA
Dose & Regimen Optimization, Including Duration
Bradley MonkFlorida Cancer Specialists, West Palm Beach, FL
Young Investigator Case Presentation
TBD
Panel Discussion
Day Two · Saturday, May 8, 2027
Session VPrecision Frontline Therapy
Moderator
DLBCL Molecular Classification: Genetics, Cell of Origin, and Therapy Selection
David ScottBC Cancer, Vancouver, BC
Frontline DLBCL in 2027: Beyond R-CHOP for Biologically High-Risk Disease
Jason WestinMD Anderson Cancer Center, Houston, TX
Indolent Lymphoma at Diagnosis: Observation, Time-Limited Therapy, or Early Immune Redirection?
Carla CasuloWilmot Cancer Institute, Rochester, NY
Panel Discussion: Can Frontline Lymphoma Therapy Become Risk-Adapted in Routine Practice?
Session VITherapeutic Vulnerabilities and Resistance
Moderator
Targeted Therapy Across B-Cell Lymphomas: BTK, BCL2, BCR Signaling, and Rational Combinations
Sonali SmithUniversity of Chicago, Chicago, IL
Degraders and Resistance: Promise, Failure Modes, and Next-Generation Targeting
Catherine DiefenbachNYU Langone Health, New York, NY
Bispecific Antibodies in Lymphoma: From Relapsed Disease to Earlier-Line Combinations
Elizabeth BuddeCity of Hope, Duarte, CA
Panel: Can Rational Combinations Prevent Lymphoma Escape Rather Than Treat Relapse After It Occurs?
Lunch Break + Faculty & Fellow Photo
Session VIIMeasuring and Overcoming Resistance
Moderator
ctDNA in Lymphoma as a Prognostic Biomarker
Ash AlizadehStanford University, Stanford, CA
ctDNA and MRD in Lymphoma: From Prognostic Biomarker to Treatment-Decision Tool
Mark RoschewskiMemorial Sloan Kettering, New York, NY
Mantle Cell Lymphoma as the Model for MRD-Adapted Frontline Therapy
Anita KumarMemorial Sloan Kettering, New York, NY
Panel Discussion: Should Molecular Relapse Trigger Treatment Before Clinical Relapse?
Session VIIIDelivering the Future of Lymphoma Care
Moderator
Spatial and Immune Features of High-Risk Lymphoma
Michael GreenMD Anderson Cancer Center, Houston, TX
Delivery of Complex Lymphoma Therapy in Community Practices
Loretta NastoupilSouthwest Oncology, CommonSpirit Mercy, Durango, CO
Learning Health Systems for Lymphoma: Real-World Data, Digital Pathology, Imaging AI, and Biospecimens
Dai ChiharaMD Anderson Cancer Center, Houston, TX
Panel Discussion: What Should the Next Generation of Lymphoma Trials Look Like?
Partnership Opportunities Now Open
Bespoke engagement packages for a closed, invitation-only audience
Request the Prospectus →
Your Point of Contact
Zeynep Aydagül
Account Executive, MD Education
zeynep.aydagul@md-education.com